Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia Agrees to Identify Lead Compounds for Boehringer Ingelheim

NEW YORK, Oct. 2 – Drug discovery company Pharmacopeia of Princeton, NJ, said Tuesday it has agreed to collaborate with German pharmaceutical company Boehringer Ingelheim to identify lead compounds for an undisclosed target.

Under the terms of the deal, Pharmacopeia will help Boehringer Ingelheim to develop assays and will provide the company with compound samples. In addition, Pharmacopeia will also provide high-throughput screening technology services.

In exchange, Pharmacopeia said it would receive fees and additional milestone payments of an undisclosed amount.

"Pharmacopeia's compound pool complements Boehringer Ingelheim's sample collection," Dieter Hinzen, head of research and development at Boehringer Ingelheim Pharma, a subsidiary of Boehringer Ingelheim, said in a statement.

"Boehringer Ingelheim expects to identify attractive lead compounds for one of our innovative targets from Pharmacopeia's large collection of small molecules," Hinzen said. 

Pharmacopeia's drug discovery unit integrates small molecule combinatorial and medicinal chemistry, high-throughput screening, in-vitro pharmacology, computational methods, and informatics to discover and optimize lead compounds. 

In addition to drug discovery, Pharmacopeia also operates a software business, Accelrys. In July, the company said it was considering spinning Accelrys off from its drug discovery businesses. 

Boehringer Ingelheim of Ingelheim, Germany is a leading pharmaceutical company.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.